32464-55-4

Usage

Uses

Used in Pharmaceutical Industry:
2-(4,4-Diethoxybutyl)-1H-isoindole-1,3(2H)-dione is used as a building block in the synthesis of pharmaceuticals for its unique properties that facilitate various chemical reactions, contributing to the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(4,4-Diethoxybutyl)-1H-isoindole-1,3(2H)-dione serves as a key intermediate in the production of agrochemicals, aiding in the creation of effective compounds for crop protection and enhancement.
Used in Advanced Materials:
2-(4,4-Diethoxybutyl)-1H-isoindole-1,3(2H)-dione is utilized in the synthesis of advanced materials, leveraging its chemical properties to produce innovative materials with specialized applications in various industries.
Used in Organic Synthesis:
As a building block in organic synthesis, 2-(4,4-Diethoxybutyl)-1H-isoindole-1,3(2H)-dione is employed for its ability to participate in a wide range of chemical reactions, enabling the creation of diverse organic compounds for multiple applications.

Upstream product

• 85-44-9 phthalic anhydride 
• 6346-09-4 4-aminobutyrylaldehyde diethylacetal 
• 22509-74-6 N-ethoxycarbonylphthalimide 
• 138076-66-1 2-(4,4-diethoxybutylcarbamoyl)benzoic acid 

Downstream Products

• 223679-00-3 4-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propyl]-6-ethyl-5-ethylsulfanylcarbonyl-2-phenyl-nicotinic acid ethyl ester 
• 1026634-99-0 4-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propyl]-6-ethyl-5-ethylsulfanylcarbonyl-2-phenyl-1,4-dihydro-pyridine-3-carboxylic acid ethyl ester 
• 146548-65-4 [1-Amino-4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyl]-phosphonic acid diphenyl ester 
• 113953-96-1 Boc->Cad<-Pua(Z)=Pht 
• 121903-75-1 Pht=Pua(Z)-OH 
• 3804-16-8 2-(7-chloro-1H-indol-3-yl)ethanamine 
• 2436-04-6 2-(7-methoxy-indol-3-yl)-ethylamine 
• 53157-46-3 N,N-phthalimido-2-(5-hydroxy-1H-indole-3-yl)ethylamine 
• 15741-71-6 N-phthalimidotryptamine 
• 1206830-87-6 C₂₄H₁₈N₂O₂ 
• 1265341-14-7 2-(4,4-difluorobutyl)isoindoline-1,3-dione 
• 1401067-58-0 2-(4-hydroxy-4-(2-nitrophenyl)butyl)isoindoline-1,3-dione 
• 1401067-72-8 2-(4-((tert-butyldimethylsilyl)oxy)-4-(2-nitrophenyl)butyl)-isoindoline-1,3-dione 
• 1621071-18-8 2-(4-hydroxy-4-(5-methyl-2-nitrophenyl)butyl)isoindoline-1,3-dione 

Relevant academic research and scientific papers

BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT

The present invention provides bisaminoquinoline compounds of Formula (I). The present invention also provides nanocarriers comprising compounds of the present invention, and methods of using the nanocarriers for treating diseases and imaging.

6-MEMBERED CYCLIC AMINES OR LACTAMES SUBSTITUTED WITH UREA AND PHENYL

The present invention relates to a compound according to general formula (I) which acts as a modulator of FPR2 and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by FPR2.

Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties

CXCR4 is a seven-transmembrane receptor expressed by hematopoietic stem cells and progeny, as well as by ≥48 different cancers types. CXCL12, the only chemokine ligand of CXCR4, is secreted within the tumor microenvironment, providing sanctuary for CXCR4+ tumor cells from immune surveillance and chemotherapeutic elimination by (1) stimulating prosurvival signaling and (2) recruiting CXCR4+ immunosuppressive leukocytes. Additionally, distant CXCL12-rich niches attract and support CXCR4+ metastatic growths. Accordingly, CXCR4 antagonists can potentially obstruct CXCR4-mediated prosurvival signaling, recondition the CXCR4+ leukocyte infiltrate from immunosuppressive to immunoreactive, and inhibit CXCR4+ cancer cell metastasis. Current small molecule CXCR4 antagonists suffer from poor oral bioavailability and off-target liabilities. Herein, we report a series of novel tetrahydroisoquinoline-containing CXCR4 antagonists designed to improve intestinal absorption and off-target profiles. Structure-activity relationships regarding CXCR4 potency, intestinal permeability, metabolic stability, and cytochrome P450 inhibition are presented.

PROTEASE INHIBITORS HAVING ENHANCED FEATURES

Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.

Compounds and methods for protease detection

Alternative methods for the detection and measurement of proteases in biological samples and compounds which allow for such detection are required to allow for rapid and selective identification of these enzymes. Compounds which allow for selective identification of these enzymes are provided with assays and kits for their use.

From in vitro to in cellulo: Structure-activity relationship of (2-nitrophenyl)methanol derivatives as inhibitors of PqsD in Pseudomonas aeruginosa

Recent studies have shown that compounds based on a (2-nitrophenyl)methanol scaffold are promising inhibitors of PqsD, a key enzyme of signal molecule biosynthesis in the cell-to-cell communication of Pseudomonas aeruginosa. The most promising molecule displayed anti-biofilm activity and a tight-binding mode of action. Herein, we report on the convenient synthesis and biochemical evaluation of a comprehensive series of (2-nitrophenyl)methanol derivatives. The in vitro potency of these inhibitors against recombinant PqsD as well as the effect of selected compounds on the production of the signal molecules HHQ and PQS in P. aeruginosa were examined. The gathered data allowed the establishment of a structure-activity relationship, which was used to design fluorescent inhibitors, and finally, led to the discovery of (2-nitrophenyl)methanol derivatives with improved in cellulo efficacy providing new perspectives towards the application of PqsD inhibitors as anti-infectives. This journal is the Partner Organisations 2014.

Discovery of tetrahydroisoquinoline-based CXCR4 antagonists

A de novo hit-to-lead effort involving the redesign of benzimidazole- containing antagonists of the CXCR4 receptor resulted in the discovery of a novel series of 1,2,3,4-tetrahydroisoquinoline (TIQ) analogues. In general, this series of compounds show good potencies (3-650 nM) in assays involving CXCR4 function, including both inhibition of attachment of X4 HIV-1IIIB virus in MAGI-CCR5/CXCR4 cells and inhibition of calcium release in Chem-1 cells. Series profiling permitted the identification of TIQ-(R)-stereoisomer 15 as a potent and selective CXCR4 antagonist lead candidate with a promising in vitro profile. The drug-like properties of 15 were determined in ADME in vitro studies, revealing low metabolic liability potential. Further in vivo evaluations included pharmacokinetic experiments in rats and mice, where 15 was shown to have oral bioavailability (F = 63%) and resulted in the mobilization of white blood cells (WBCs) in a dose-dependent manner.

AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS

A compound satisfying formula I, a prodrug, N-oxide, addition salt, quaternary metal complex, or a stereochemically isomeric form thereof; (formula I) compositions contain these compounds as active ingredient and processes for preparing these compounds and compositions.

Validation of PqsD as an anti-biofilm target in pseudomonas aeruginosa by development of small-molecule inhibitors

2-Heptyl-4-hydroxyquinoline (HHQ) and Pseudomonas quinolone signal (PQS) are involved in the regulation of virulence factor production and biofilm formation in Pseudomonas aeruginosa. PqsD is a key enzyme in the biosynthesis of these signal molecules. Using a ligand-based approach, we have identified the first class of PqsD inhibitors. Simplification and rigidization led to fragments with high ligand efficiencies. These small molecules repress HHQ and PQS production and biofilm formation in P. aeruginosa. This validates PqsD as a target for the development of anti-infectives.

ACYCLIC 1,4-DIAMINES AND USES THEREOF

This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain acyclic diamines, which are agonists of TRPV4 channel receptors.